Biocon Biologics to launch Trastuzumab, Nivolumab, Pembrolizumab biosimilars for cancer. Expanding oncology portfolio.

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going ...

As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through their battles, and professionally in the pharmaceutical space—I've been ...

Stage 4 RCC is metastatic, with common spread to lungs, bones, liver, brain, and adrenal glands. Understanding IMDC risk is ...

Biocon Biologics plans to introduce three oncology biosimilars, enhancing its cancer treatment portfolio. They will unveil ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Amgen AMGN announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 ...

Biocon Biologics is set to unveil three new biosimilar oncology assets — Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo), and Pembrolizumab (Keytruda) — at the 2026 JP ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Value stocks aren't typically the most exciting investments, but they can often provide steady capital gains without causing investors to lose any sleep during periods of market volatility.

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...